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Available online 7 June 2016Niemann-Pick disease type C (NP-C) is a neurovisceral lysosomal cholesterol trafﬁcking and lipid storagedisorder
caused by mutations in one of the two genes, NPC1 or NPC2. Diagnosis has often been a difﬁcult task, due to the
wide range in age of onset of NP-C and clinical presentation of the disease, combined with the complexity of the
cell biology (ﬁlipin) laboratory testing, even in combination with genetic testing. This has led to substantial de-
lays in diagnosis, largely depending on the access to specialist centres and the level of knowledge about NP-C
of the physician in the area. In recent years, advances in mass spectrometry has allowed identiﬁcation of several
sensitive plasma biomarkers elevated in NP-C (e.g. cholestane-3β,5α,6β-triol, lysosphingomyelin isoforms and
bile acid metabolites), which, together with the concomitant progress in molecular genetic technology, have
greatly impacted the strategy of laboratory testing. Speciﬁcity of the biomarkers is currently under investigation
and other pathologies are being found to also result in elevations. Molecular genetic testing also has its limita-
tions, notably with unidentiﬁed mutations and the classiﬁcation of new variants. This review is intended to in-
crease awareness on the currently available approaches to laboratory diagnosis of NP-C, to provide an up to
date, comprehensive and critical evaluation of the various techniques (cell biology, biochemical biomarkers
and molecular genetics), and to brieﬂy discuss ongoing/future developments. The use of current tests in proper
combination enables a rapid and correct diagnosis in a large majority of cases. However, even with recent prog-
ress, deﬁnitive diagnosis remains challenging in some patients, for whom combined genetic/biochemical/cyto-
chemical markers do not provide a clear answer. Expertise and reference laboratories thus remain essential,
and further work is still required to fulﬁll unmet needs.
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Niemann-Pick disease type C (NP-C; NP-C1 OMIM #257220, NP-C2
#607625) is a rare, autosomal recessive neurovisceral, lysosomal choles-
terol trafﬁcking and lipid storage disorder, caused by mutations in one of
the two genes, NPC1 or NPC2. It is characterised by accumulation of a
broad range of lipids, including unesteriﬁed cholesterol and various
sphingolipids, in the lysosomes and late endosomes [1–8]. The accumula-
tion of lipids in NP-C is likely to be the crucial event in disease pathogen-
esis, but our understanding of the mechanisms leading to lipid storage,
and those causing neurodegeneration, remains incomplete [7–9].
NP-C has a variable age of onset, and a range of non-speciﬁc visceral,
neurological and psychiatric clinical features that can arise at different
stages of disease, and progress at different rates [4,10]. Birth incidences
calculated from patients diagnosed with NP-C were reported as 0.83/
0.96 and 0.93:100,000 in two studies [4,11], although this has to be an
underestimate, with many patients going undetected [12]. A recent
analysis of massively parallel exome sequencing data sets has predicted
an incidence, at conception, of 1.12:100,000 for common forms of NP-
C—close to the incidence of observed cases—but suggested a higher in-
cidence of unrecognised mild, late-onset forms of the disease [13].
There are a number of factors that delay the initial suspicion, andhence
the ﬁnal diagnosis of NP-C. The initial clinical presentation is non-speciﬁc
which, combined with limited awareness of NP-C in general clinical prac-
tice, makes detection and clinical diagnosis difﬁcult. Despite increased un-
derstanding of the genetics and biochemistry of NP-C, laboratory testing
has remained complex, restricted to a few specialist centres, and associat-
edwith substantial costs. Although national and regional specialist centres
do exist, diagnostic testing is still limited by disease awareness, test
availability and cost in some parts of the world, often leading to a major
delay between onset of symptoms, diagnosis, and treatment initiation.
Recommendations for diagnosis andmanagement of NP-C have been
published previously [10,14]. InMay 2013, a panel of experts gathered in
Zurich, Switzerland, to discuss the latest advances in understandingof the
genetics of NP-C. It was agreed that there was a need for a critical review
of the current approaches in the laboratory diagnosis of NP-C, including
emerging screening tests. Amuchbetter understanding of the advantages
and limitations of the latter tests has now been achieved, making such a
survey timely. This review is not intended to provide recommendations
or algorithms for order of testing, but it will brieﬂy discuss the unmet
needs and expectations for the future of NP-C diagnostics.
2. Clinical examination
Clinical history and examination are the initial steps undertaken be-
fore considering further diagnostic procedures [10,14]. A detailedexamination can, in some cases, help distinguish NP-C from other
neurometabolic disorders [14]. However, the clinical presentation of
NP-Cmay varywidely depending on the disease stage, and can even dif-
fer between individuals with similar genotypes, making accurate as-
sessment particularly difﬁcult if based on clinically presenting features
alone. Therefore, similar to other inherited metabolic disorders, conﬁr-
matory laboratory tests are always required [10].
Signs and symptoms of NP-C can be broadly grouped into three cat-
egories: visceral, neurological and psychiatric [10,12,15,16]. Patients
with NP-C typically present with some characteristic signs and symp-
toms from across these categories, which can be used to help identify
the disease. These include, but are not limited to, neonatal cholestatic
jaundice, splenomegaly, vertical supranuclear gaze palsy (VSGP),
gelastic cataplexy, ataxia, dysphagia, dystonia, cognitive impairment
and psychosis. SpeciﬁcNPC1 orNPC2mutations are associatedwith cer-
tain clinical subtypes of NP-C, particularly the age of onset of neurolog-
ical symptoms [4]. The heterogeneity of NP-C and presence of
symptoms that overlap with other diseases complicate the diagnostic
process, leading to a long delay between symptom presentation and ac-
curate diagnosis. Another working diagnosis is often not questioned
until additional manifestations occur. The combined presence of viscer-
al, neurological and/or psychiatric symptoms should lead to consider-
ation of NP-C in the differential diagnosis; however, atypical NP-C
patients are not infrequent. Examples include adult patients who have
purely psychiatric symptoms and patients of any age with only visceral
manifestations. In both instances theremay be no evidence of neurolog-
ical involvement at the time of diagnosis.
The clinical heterogeneity of initial presentation means that the pa-
tientsmayﬁrst be seen by generalist physicians or clinicians fromdiffer-
ent specialties [10,14]. The NP-C Suspicion Index (SI) screening tool
(www.NPC-SI.com) was developed to aid clinicians in early identiﬁca-
tion of patients older than 4 years of age with suspicion of NP-C [15,
17]. The tool generates a risk prediction score based on the presence
of speciﬁc clinical manifestations and family history to identify patients
who should be referred for further investigation of NP-C.3. Current laboratory diagnostic techniques
Laboratory-based tests are the mainstay of diagnostic procedures in
NP-C. Previously, such tests were initiated in case of a clear clinical sus-
picion of NP-C. Considering the often non speciﬁc/atypical features in
some patients andmethodological progress, there is (andwill be) an in-
creasing trend to includeNP-C inwider biochemical ormolecular genet-
ics diagnostic panels. Nevertheless, each of the current approaches has
limitations, as discussed below. Diagnostic testing should therefore be
246 M.T. Vanier et al. / Molecular Genetics and Metabolism 118 (2016) 244–254conducted at, or in consultationwith, specialised centreswith extensive
experience [10].3.1. Cell biology – studying intracellular trafﬁcking of LDL-derived
cholesterol
NP-C is characterised by a unique disruption in intracellular trans-
port of endocytosed cholesterol. Both the NPC2 and NPC1 proteins are
necessary for egress of endocytosed cholesterol from late endosomes
(LE)/lysosomes (L) (reviewed in [7,8]). Consequently, when either pro-
tein is dysfunctional, loading cells with low density lipoprotein (LDL)
will lead to cholesterol accumulation in the LE/L compartment, which
can be visualised after ﬁlipin staining [18]; this is the principle of the
ﬁlipin test. Cholesterol sequestration secondarily retards all LDL-in-
duced homeostatic responses [19], more speciﬁcally cholesteryl ester
formation by acyl-CoA:cholesterol acyltransferase (ACAT) [1], which
can be measured with the so called ‘cholesterol esteriﬁcation test’.
An overview of the advantages and limitations of the cell biological
tests is shown in Table 1.Table 1
Cell biology diagnostic techniques in NP-C: an overview of advantages and limitations.
Technique Advantages Limitations
Filipin staining of cultured
skin ﬁbroblasts
(cytochemistry after
cholesterol depletion and
in vivo challenge with
LDL; ﬂuorescence
microscopy evaluation;
semi-quantitative)
• N80% of NP-C cases
display a typical (‘clas-
sical’ or ‘intermediate’)
staining proﬁle
• Similar results in
NP-C1 and NP-C2
• Typical staining proﬁle is
unambiguous and easy
to interpret—with clini-
cal ﬁndings it supports
conﬁdent diagnosis
• Longest experience in a
broad clinical
setting—well-deﬁned
limitations
• Invasive skin biopsy
and cell culture
• Turnaround time (5
weeks for culture, 2
weeks for testing); cost
• Technical requisites:
speciﬁc biological re-
agents; positive and
negative reference cells
in each assay; adequate
microscopic conditions
• Rigorous conditions and
expertise in interpreta-
tion are critical for the
following reasons:
− ‘Variant’ staining pro-
ﬁle (~15% of NP-C
cases) with fewer and
varied number of
positive cells can be
difﬁcult to interpret
− NP-C heterozygotes
and other diseases
(e.g. NP-A/B) may
produce mildly posi-
tive results, difﬁcult
to distinguish from
‘variant’
• Final interpretation of
‘variant’ or ‘inconclu-
sive’ proﬁles requires
complementary testing
(NPC1/NPC2 sequencing
or other)
Cholesterol esteriﬁcation
test
(early LDL-induced
cholesteryl ester
formation, measured after
cholesterol depletion and
in vivo challenge with
LDL; extract, separate and
quantify radioactive
product)
• Was very useful as sec-
ond test prior to iden-
tiﬁcation of NPC1/NPC2
mutations
• Clear-cut results in
typical NP-C cases
• Differentiates NP-C
from NP-A/B and some
other diseases
• Skin biopsy and cell
culture
• Turnaround time; very
labour intensive; high
cost
• Speciﬁc biological re-
agents; use of a 3H radio-
active precursor
• Large inter-assay varia-
tions
• Less sensitive than the
ﬁlipin staining test (‘vari-
ant’ often missed)
LDL: low-density lipoprotein; NP-A, -B, -C: Niemann-Pick disease types A, B, C.3.1.1. Filipin test
Developed 30 years ago, the ﬁlipin test has been extensively used,
and until recently was considered as the gold standard assay for NP-C
diagnosis [1,4,14,20]. Filipin is a ﬂuorescent polyene antibiotic, which
speciﬁcally binds to cholesterol but not to esteriﬁed sterols. It cannot
be used in living cells because it perturbs the cell bilayer [21], and stain-
ing must therefore be done on ﬁxed cells/tissue sections. In the original
protocol, sparsely seeded skin ﬁbroblasts, cultivated on slide chambers,
were fed for several days with medium supplemented with 10% lipo-
protein-deﬁcient serum (LPDS) to maximise LDL-receptors, then incu-
bated for 24 h in medium enriched with 100 μg/mL LDL. Cells were
then ﬁxed in 10% buffered formalin, before ﬁlipin staining and ﬂuores-
cence microscopy examination [18]. Although minor modiﬁcations
can be performed, extensive experience has shown that, globally, this
relatively complex set-up is optimal.
Early studies showed that in ﬁbroblast cultures from normal
subjects, fewer than 10% of cells stain positive, while in those from
typical NP-C patients, nearly all cells display multiple strongly ﬂuo-
rescent perinuclear vesicles [18]. Studies in large series of patients
[20,22–25] indicate that this typical pattern is observed in 80–85%
of cases with NP-C, even when cells are challenged with a lower con-
centration of LDL. Subdivision of the typical staining pattern into
‘classical’ and ‘intermediate’ proﬁles has been proposed to reﬂect a
variation in the percentage of positive cells (80 to 100% of cells)
and their level of ﬂuorescence, resulting in a small gradient for ﬁlipin
positivity that also correlates with LDL-induced cholesteryl ester for-
mation levels [20,23]. In both typical sub-proﬁles, interpretation of
the test is always very easy and unambiguous. Only one condition,
mucolipidosis II/III (I-cell disease) is known to mimic a typical/clas-
sical NP-C ﬁlipin proﬁle [20], and it has been shown that the NPC2
protein is non-functional in I-cell ﬁbroblasts [26,27]. However, in
clinical practice, this is not a problem considering the widely differ-
ent presentations of the diseases.
In the remaining 15–20% of NP-C cases, the block in cellular choles-
terol trafﬁcking is signiﬁcantly less severe (although to a variable de-
gree), and can only be demonstrated if cells are challenged with high
concentrations of pure LDL. Stringent conditions are required to observe
a signiﬁcant number of ﬂuorescent perinuclear vesicles (seen in 50–80%
of cells only). This pattern has been described as the ‘variant’ proﬁle [20,
23]. Conﬁrming a diagnosis of NP-C solely from the ﬁlipin test can be
particularly difﬁcult in a proportion of cases with a ‘variant’ proﬁle be-
cause, as discussed below, an NP-C heterozygous status [18] as well as
a number of pathological conditions can also result in mild alterations
in the ﬁlipin test. In case of a ‘variant’ pattern, complementary sequenc-
ing of the NPC1 and NPC2 genes is recommended before making a con-
clusive diagnosis [10,23].
A number of studies have shown that a ‘variant’ proﬁle can be relat-
ed to speciﬁc NPC1mutations, and that it can prevail even when these
mutations are present in a compound heterozygous status [28–30]. No-
tably, p.P1007A, one of the two most common NPC1 mutations, is al-
most invariably associated to a “variant” proﬁle [22,28,29]. Compared
with the UK and USA, Spain or France [22,24,25,31], this mutation has
been described with a more than double frequency (10% of mutant al-
leles) in patient cohorts from Germany [32] and Czech Republic [11].
A higher proportion of “variant” patients is thus expected in these and
possibly some other countries. Case studies have also indicated that
the ‘variant’ proﬁle is more common in the adult neurological onset
form than in juvenile or late-infantile forms of the disease [23,33],
while patients with early-infantile neurological onset show a classical
pattern. Since cells from many late-onset patients also show a typical
proﬁle, no strict correlation can be made between the cholesterol traf-
ﬁcking abnormality and the severity of neurological involvement [20,
22,23,30,33–35]. In practice, the higher prevalence of the ‘variant’ ﬁlipin
proﬁle in late-onset neurological forms of the disease adds to the difﬁ-
culty of diagnosing adults with NP-C, often less typical in their clinical
presentation.
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ﬁlipin test, incurring the risk of a false positive NP-C diagnosis. Among
them, acid sphingomyelinase deﬁciencies (ASMDs; Niemann-Pick dis-
ease typeA and type B [NP-A/-B])—one of the commondifferential diag-
noses of NP-C—constitute a signiﬁcant pitfall [23]. Sphingomyelin
storage is likely to affect cholesterol transfer by the NPC2 protein [7],
and indeed, secondary cholesterol storage occurs inmost ASMD tissues.
For acid lipase deﬁciencies (Wolman disease and cholesteryl ester stor-
age disease) conﬂicting results have been reported by different labora-
tories. Abnormal ﬁlipin patterns have further been documented in
MEGDEL syndrome [36] and in diseases likely to secondarily affect lyso-
somal cholesterol egress, such as Smith-Lemli-Opitz syndrome [37], and
Tangier disease [38]. Following the implication of Nogo-B receptor in-
volvement in NPC2 protein stability [39], abnormal ﬁlipin staining re-
sults were also described in a rare congenital disorder of glycosylation
due to Nogo-B receptor mutations [40]. Finally, although no suchmuta-
tions have been described in humans,mouse cells deﬁcient inmannose-
6-phosphate receptors MPR46 andMPR300, showed altered ﬁlipin pro-
ﬁles (38% and 20% of positive cells, respectively) [26]. Implication of
other cholesterol-sensor or transporter proteins closely related to
NPC1, such as members of the oxysterol-binding protein-related pro-
tein family [41–43] are further candidates for false positive results in
ﬁlipin testing.
More clinically relevant, although not systematically reviewed, a
number of lysosomal storage disorders (LSDs) could potentially result
in mildly abnormal ﬁlipin patterns. Indeed, elevated free cholesterol
has been found in LSD cells. This mechanism was advocated as the
cause of altered trafﬁcking of the ﬂuorescent sphingolipid analogue,
BODIPY-lactosylceramide [44], a feature shared bymany LSDs including
NP-C [45]. Interestingly, BODIPY-lactosylceramide trafﬁcking was not
found to be abnormal in ‘variant’ NP-C cells, unless cells were ﬁrst chal-
lenged with high LDL concentrations, as required to optimise the ﬁlipin
test [22].
Finally, extensive studies have been performed in parents of affected
children with a ‘classical’ ﬁlipin proﬁle. Fibroblasts from heterozygous
subjects frequently display slightly abnormal ﬁlipin proﬁles, sometimes
similar to those of patients with a ‘variant’ proﬁle [46]. This should be
kept inmind, and such an observationmay lead to a dilemmawhenever
only one mutant NPC1 or NPC2 allele is identiﬁed in a potential NP-C
patient—is the individual a ‘variant’ patient with one unidentiﬁed allele
or an NP-C heterozygote with another disease?
A major drawback of the ﬁlipin test is that it requires living ﬁbro-
blasts cultured from a skin biopsy. This incurs invasive sampling, the
need for a cell culture facility and a long (5–7 weeks) turnaround
time. Attempts to use cultured lymphocytes [47] proved unsuccessful
in clinical practice. Similarly, the work in a publication proposing the
use of blood smears [48] has not been replicated. Other limitations in-
clude the requirement for costly LPDS and LDL reagents, the need to in-
clude positive and negative control cells in all experiments and,
considering the pitfalls outlined above, the necessary experience in in-
terpretation to ensure accurate results [23]. This restricts testing to a
small number of expert centres. Results from ‘variant’ or inconclusive
tests must be evaluated in light of the clinical presentation, and
complemented by sequencing of the NPC1 and NPC2 genes [10,23].
When nomutations are detected, clinical data and additional NP-C bio-
chemical testsmust be reviewed, other diagnoses considered and, even-
tually, ﬁlipin tests repeated in another laboratory. Notwithstanding, the
ﬁlipin test remains a valid tool for the laboratory diagnosis of NP-C and
constitutes so far the best functional test to study the pathogenicity of
novel mutations.
3.1.2. Cholesterol esteriﬁcation test
The cholesterol esteriﬁcation test measures the early rate of
cholesteryl ester formation elicited by LDL loading of cholesterol-de-
pleted cells [20], and evaluates the re-esteriﬁcation by ACAT of choles-
terol generated from LDL endocytosis after its egress from the LE/Lcompartment. This crucial homeostatic reaction is particularly impaired
in NP-C cells [19]. Discovery of this defect constituted the initial break-
through in the concept of NP-C as a cellular cholesterol dysregulation
disease [1].
The test requires two sets of cells initially maintained for several
days in a LPDS-supplemented medium, and then fed [3H]oleic acid, ei-
ther in LPDS or in LPDS/LDL medium, for 4–6 h. Cells are harvested,
lipids extracted and separated, radioactivity of cholesteryl oleate quan-
tiﬁed and reported to cell protein, and the difference between the two
media conditions calculated. In cells with a ‘classical’ ﬁlipin proﬁle, the
early rate of LDL-induced cholesteryl ester formation is essentially nil,
while cells with an ‘intermediate’ ﬁlipin proﬁle show a moderate deﬁ-
ciency. In ‘variant’ cells, cholesteryl oleate formation is often in the
low normal range. In NP-C heterozygotes, cholesteryl oleate formation
appears normal or mildly deﬁcient [20].
Like theﬁlipin test, the cholesterol esteriﬁcation test requires a living
cell culture, but the assay is more complex, more labour intensive, and
costly. Controlled conditions for all cell culture steps are essential, ne-
cessitating mandatory positive and negative controls. Even so, large
inter-assay variations still occur. The radioactive precursor is a further
limitation. Since the test has proved less sensitive than ﬁlipin staining,
very few laboratories still perform it as part of the NP-C diagnostic pro-
cess. While very useful as a complementary test before genotyping was
possible, its current use is now essentially limited to research settings.
3.2. Biochemical biomarkers
To allowwider screening for NP-C, there was a clear need for conve-
nient blood-based, cost-effective, and if possible speciﬁc, biomarkers.
The study of chitotriosidase activity was for a long time the only ap-
proach. In recent years, assays for several new, more sensitive and spe-
ciﬁc metabolites have been developed. These have shown promise for
NP-C and are used with increasing frequency in clinical practice as the
primary screening test. An overview of these techniques, and their
projected advantages and limitations, is provided in Table 2.
3.2.1. Chitotriosidase activity
Measurement of plasma chitotriosidase activity, available in many
laboratories, has shown its usefulness as a biomarker of Gaucher dis-
ease. Demonstration of mild to moderate elevation is also widely used
as a general and potential indicator of lysosomal storage diseases, in-
cluding NP-A, -B and -C [49]. But normal chitotriosidase activity may
occur in patients with NP-C,most notably in late-onset forms of the dis-
ease. Furthermore, elevated chitotriosidase activity has been noted in
other conditions, including more common disorders such as stroke
and type 2 diabetes mellitus [50–55]. Finally, partial or total deﬁciency
in chitotriosidase activity due to a 24 bp duplication in the
chitotriosidase gene is relatively frequent [56]. As such, the assay lacks
speciﬁcity and sensitivity for NP-C.
3.2.2. Oxysterol analysis
Besides the characteristic lysosomal accumulation of unesteriﬁed
cholesterol, oxidative stress leading to increased production of reactive
oxygen species has been demonstrated in cultured ﬁbroblasts from pa-
tients with NP-C [57,58], NPC1 ablated neuronal cell lines [58] and
Npc1−/−mice [59].
Oxidative stress situations are known to lead to the non-enzymatic
formation of cholesterol auto-oxidation products. Early work docu-
mented elevation of several oxysterols in tissues of Npc1−/−mice [60].
Reappraisal studies showed that two metabolites, cholestane-
3β,5α,6β-triol (C-triol) and 7-ketocholesterol (7-KC),were of particular
interest. These metabolites were found elevated in the blood plasma of
Npc1−/− mice [59] and patients with NP-C, while a modest elevation
was seen in NPC1 heterozygotes [61,62]. Plasma oxysterol-based tests
were then proposed for rapid diagnosis of NP-C using gas chromatogra-
phy–mass spectrometry (GC/MS) [61], or liquid chromatography-
Table 2
Plasma and urinary diagnostic biomarkers in NP-C: an overview of advantages and
limitations.
Technique Advantages Limitations
Plasma oxysterol
testing
(LC-MS/MS or
GC–MS;
quantitative)
• Elevated in the majority
of patients with NP-C
(NP-C1 and NP-C2)
• Minimally-invasive –
small volume of frozen
EDTA plasma or serum
• Rapid analysis – results
often available within 1
week
• Able to identify the majori-
ty of adult patients
• Suitable for analysis of a
large number of samples
• Cost savings versus ﬁlipin
testing
• Unspeciﬁc – 7-KC and C-triol
are elevated in other diseases.
Even the more speciﬁc C-triol
does not distinguish NP-C
from NP-A/B, acid lipase
deﬁciency and some other
conditions (including CTX
and some causes of neonatal
cholestasis)
• Possibility of false positive
results due to incorrect han-
dling or storage of samples
• Limited knowledge of range
values in heterozygotes
• Not applicable to dry blood
spots
Plasma
lysosphingolipids
(LC-MS/MS;
quantitative)
• Minimally-invasive –
small volume of blood
• Potential for fewer pre--
analytical problems ver-
sus oxysterol testing
• Concomitant study of
lyso-SM-509 and SPC dif-
ferentiates NP-C
• High throughput
• Multiplex assay can identi-
fy other LSDs –meet
demands; faster
turnaround time
• Cost savings versus ﬁlipin
testing
• Lyso-SM-509 does not
clearly distinguish NP-C
from NP-A/-B
• SPC alone does not have
sufﬁcient sensitivity as an
NP-C biomarker
• Experience in clinical labo-
ratory setting is still limited
Bile acid
metabolites
plasma; dried
blood spots; urine
(LC-MS/MS;
quantitative)
• Non- or minimally-
invasive
• Current data indicate good
discriminatory power
• Cost savings versus ﬁlipin
testing
• Also elevated in NP-A/B
• Possibly other diseases?
• Experience in clinical labo-
ratory setting still lacking
C-triol: cholestane-3β,5α,6β-triol; CTX: cerebrotendinous xanthomatosis; GC: gas chro-
matography; 7-KC: 7-ketocholesterol; LC: liquid chromatography; LSDs: lysosomal stor-
age disorders; Lyso-SM-509: lysosphingomyelin-509; MS: mass spectrometry; NP-A, -B,
-C: Niemann-Pick disease types A, B, C; SPC: sphingosylphosphorylcholine
(lysosphingomyelin).
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chemical ionization source (LC-APCI-MS/MS) [62]. Several modiﬁed
electro spray ionization LC-ESI-MS/MS methods [63–65], LC-APCI-MS/
MS [66] and GC/MS methods [67,68] have since been developed and
validated.
All reports have demonstrated elevated oxysterols in patients with
NPC1 [61–63,66,68–72] or NPC2mutations [63,68,73]. Individual data
were also reported in two NP-C patient surveys [32,74]. Borderline or
no distinct elevation has, however, been reported in some patients
[32,62,68,75]. A very strong correlation is seen between C-triol and 7-
KC, while a relatively weak correlation with disease severity and age
of onset has been reported [61,65]. Oxysterol levels, however, do not
necessarily correlate with a patient's ﬁlipin staining proﬁle: elevated
oxysterol levels have been described in well-characterised patients
with ‘variant’ ﬁlipin proﬁles [32], but the opposite has also been ob-
served (P. Latour and C. Pagan, unpublished data).
C-triol appears to have greater discriminatory power than 7-KC for
patients with NP-C versus normal subjects, as evidenced by receiver op-
erating characteristic area under the curve analysis [61–63,65,68]. Glob-
ally, the high sensitivity of C-triol and 7-KC in detecting patients with
NP-C has been largely conﬁrmed.
On the other hand, an early conclusion of an exclusive speciﬁcity of
these biomarkers for NP-Cwas premature, as too few disorders were in-
cluded in the initial study [61]. Both C-triol and 7-KC have now been
shown to be elevated in NP-A and NP-B [64,66,68,72,75,76], lysosomalacid lipase deﬁciencies [65,68,72,75,77], and cerebrotendinous
xanthomatosis [65,78]. An isolated elevation of 7-KC has further been
reported in Smith-Lemli-Opitz syndrome [65,77,78] and in a number
of patients with peroxisomal disorders [65]. Normal results have been
observed in several other lysosomal storage diseases, including Gaucher
disease [61,76,77], in patients with various liver and neurologic involve-
ment, as well as in familial hypercholesterolemia [65]. But elevated
oxysterol results should be interpreted with caution in cholestatic neo-
nates, in view of a recent publication [79].
Finally, small but signiﬁcant elevations in C-triol and 7-KC have been
reported in 25% and 36% of NPC1mutation carriers, respectively [62], a
ﬁnding conﬁrmed in another study [66]. A potential discrimination
problem could thus arise in subjects suspected to suffer from NP-C
and showing borderline C-triol elevation, a ‘variant’ ﬁlipin proﬁle, and
only one mutated NPC1 or NPC2 pathogenic allele.
Oxysterol testing for NP-C (and NP-A/-B) is currently offered in a
limited, but growing number of laboratories. As a primary screening
test for NP-C it has many advantages for both patients and clinicians.
The test requires frozen EDTA plasma or serum—less invasive than a
skin biopsy—and plasma oxysterol levels can be quickly analysed. The
more speciﬁc C-triol should be preferred. The running cost of the
oxysterol assay is much less than traditional tests, and the procedure
can be adapted to high-throughput testing. But it also has its limitations.
The assay requires rigor in pre-analytical handling [80], and falsely ele-
vated results (particularly for 7-KC) can occur due to haemolysis or in-
adequate sample storage and transport. Access to sensitive GC/MS or
LC-MS/MS machines is another potential limitation.
The utility of the C-triol measurement has recently been demon-
strated through the identiﬁcation of 72 new patients with NP-C1 or
NP-C2 over the course of 3 years [68]. Provided other causes of elevation
are kept in mind, due to its non-invasive nature, low cost, short turn-
around time and good sensitivity, oxysterol testing constitutes a highly
useful primary test when there is suspicion of NP-C.3.2.3. Lysosphingolipids
Lysosphingolipids are sphingolipids lacking their N-acyl group, and
the lyso-counterpart of the primary stored compound has been found to
be elevated in tissues of a number of sphingolipidoses. Lysosphingolipids
are thought to be ‘toxicmetabolites’ that contribute to disease pathophys-
iology [81,82]. Plasma globotriaosylsphingosine and glucosylsphingosine
have been found to be excellent plasma biomarkers in Fabry disease
[83] and Gaucher disease [84], respectively, with levels in these patients
more than 10-fold above normal. Measurement of increases in
galactosylsphingosine and sphingosylphosphorylcholine (SPC;
lysosphingomyelin) in dried blood spots have also been proposed for
screening of Krabbe disease and NP-B [85,86]. Currently, the measure-
ment of lysosphingolipids is performed using LC-MS/MS.
NP-C is characterised by tissue-speciﬁc accumulation of several
lipids, including cholesterol, sphingomyelin, multiple
glycosphingolipids and free sphingoid bases (reviewed in [7]. Although
the mechanism for sphingolipid storage is complex and different from
that seen in primary sphingolipidoses [87], the observed tissue lipid
proﬁle accumulation led to the hypothesis that plasma
lysosphingolipids might also be biomarkers for NP-C [74,88].
An initial prospective study indicated that SPC could be elevated in
plasma in patients with NP-C [74]. A retrospective study from the
same team, applying a validated method to 70 control subjects and 22
treatment-naïve patients with NP-C, found a 2.8-fold median elevation
of SPC in the NP-C group, with only minor overlap with control values
[88]. The SPC increase in patients with NP-C was also found to be inde-
pendent of age [88]. Other laboratories have since implemented mea-
surement of plasma SPC and presented preliminary ﬁndings [89,90].
SPC was found to be elevated more than 10-fold in NP-A and NP-B,
while the increase in NP-C wasmodest, with variable overlap with con-
trols [91,92].
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ative (MW 508), currently referred to as lysosphingomyelin-509 (lyso-
SM-509). This particular isoform showed a very large increase in pa-
tients with NP-C, with even higher levels in NP-A and NP-B [93], and
preliminary data from two additional laboratories conﬁrmed these ﬁnd-
ings [89,90]. Due to the absence of an authentic standard for lyso-SM-
509, calculated concentrations probably deviate from the true concen-
tration; however, relative quantitation of lyso-SM-509 clearly offers a
powerful tool for differentiating patients with NP-C and NP-A/-B from
control subjects. As there is some overlap between lyso-SM-509 levels
observed in NP-C and NP-A/-B, co-measurement of the classical SPC iso-
form may allow clear differentiation of NP-A/-B from NP-C. Similar to
the oxysterol markers, in the coming years we will gain a better under-
standing ofwhich disorders outside of classical LSDsmay affect the level
of lysosphingolipids. Metabolic syndrome has been found to lead to el-
evated plasma SPC, although a differential diagnosis with NP-C is highly
unlikely given the differing symptomatology [94]. The recent observa-
tion that patients with action myoclonus-renal failure syndrome and
the related LIMP2−/−mousemodel have elevated glucosylsphingosine,
without concomitant increases in the equivalent sphingolipid, indicates
that sphingolipidosis is not an absolute requirement for elevatedplasma
lysosphingolipid [95,96].
Lysosphingolipid studies offer a number of advantages. Using LC-
MS/MS systems, high-throughput and multiplex testing is achievable,
and there is the potential for simultaneous screening for several
sphingolipidoses such as Gaucher disease, Fabry disease and some
neurolipidoses. This will offer beneﬁts with respect to implementation,
costs and the frequency at which tests are run.
3.2.4. Bile acid metabolites
A unique C24 bile acid, 3β-sulfooxy-7β-N-acetylglucosaminyl-5-
cholen-24-oic acid (SNAG-Δ5-CA) and its glycine- and taurine-conju-
gates were identiﬁed in high concentrations in the urine of a patient
withNP-C [97]. Itwas subsequently hypothesised that the altereddistri-
bution of cholesterol in patients with NP-C may result in utilisation of
different bile acid synthesis pathways compared with healthy individ-
uals. Using an LC-MS/MS assay, concentrations of these urinary bile
acids were found to be elevated in 2 patients with NP-C compared
with healthy controls [98], suggesting urinary bile acids as potential bio-
markers of NP-C.
Active research has further been conducted in two independent lab-
oratories. Two bile acid metabolites elevated in NP-C, 3β-hydroxy-7β-
N-acetylglucosaminyl-5-cholenoic acid and N-(3β,5α,6β-trihydroxy-
cholan-24-oyl)glycine, have been identiﬁed, and assays for their mea-
surement using tandem mass spectrometry have been validated [99,
100]. The latter compound appears to provide better discrimination be-
tween NP-C patients and carriers than the corresponding cholestane-
triol; however, its origin implies that it does not discriminate NP-C
from acid sphingomyelinase deﬁciencies. More importantly, the assays
do not require derivatization, are less prone to artefacts than oxysterol
measurements, and are applicable to both plasma and dried blood
spots [99,100]. Currently available data thus appear very promising,
suggesting that bile acid biomarkers may replace oxysterols in the
near future.
3.2.5. Bis(monoacylglycero)phosphate
Bis(monoacylglycero)phosphate (BMP or LBPA) is an atypical phos-
pholipid, particularly enriched in the late endosomes, which plays a
major role in both cholesterol processing and sphingolipid degradation
in the LE/L (reviewed in [7]). A pathological increase in BMP in several
tissues has been described in NP-A, -B and -C and drug-induced
phospholipidoses (reviewed in [101]), and in plasma and ﬁbroblasts
in various lysosomal disorders [102]. Non-clinical studies in urine
[103,104] and plasma [105] have also shown its potential in monitoring
drug-induced phospholipidosis. Recently, Liu and colleagues demon-
strated a 50-fold increase of di-22:6-BMP in the urine of patients withNP-C [106]. Whether this will be of clinical utility in NP-C is still
unknown.
3.3. Genetic testing
NP-C is caused by autosomal recessive mutations in either the NPC1
(~95% of cases) or NPC2 genes (~5% of cases) [10]. About 380 distinct
NPC1 and 22 NPC2 mutations are already known and are recorded in
mutation databases [107–109], with only a few of them being common
or recurrent. Althoughmissense and nonsensemutations constitute the
vast majority of known NP-C mutations, small and large genomic dele-
tions, as well as deep intronic mutations, have also been described [25,
29,109,110].
Genetic analysis is necessary to conﬁrm a diagnosis of NP-C follow-
ing abnormal results with disease biomarkers or inconclusive ﬁlipin
staining results [10,23], but identiﬁcation of NPC1 or NPC2 mutations
should also optimally complement even clear-cut results from ﬁlipin
staining [10]. Although, until recently, it was predominantly used as a
conﬁrmatory diagnostic method in NP-C, rather than as an initial diag-
nostic procedure, with the much better availability of newest sequenc-
ing methods, primary exon and junction sequencing of both the NPC1
andNPC2 genes is becoming increasingly common as part of the routine
diagnostic process, and has been recommended to be performed in all
patients [10,108].
The identiﬁcation of two alleles with demonstrated disease-causing
mutations in NPC1 or NPC2 conﬁrms the diagnosis of NP-C, with
supporting mutation analysis in at least one parent. Attention needs
however to be paid to the source of genotype–phenotype veriﬁcation,
as some polymorphisms (e.g. p.P237S in NPC1 [111]) are known to be
erroneously registered in mutation databases as disease causing muta-
tions. As with other testing methods, routine genetic sequencing tech-
niques sometimes fail to identify mutations or may provide
inconclusive results [74]. Sanger sequencing of gDNA and cDNA is cur-
rently the most widely used technique for genetic analysis in NP-C
[108], allowing targeted sequencing, validation of diagnoses based on
other positive tests, and identiﬁcation of hard-to-ﬁnd mutations [25].
Next-generation sequencing (NGS) techniques are becoming increas-
ingly more cost-effective and accessible for genetic analysis in NP-C
[108], and can be highly valuable for screening in patients with speciﬁc
phenotypes.
Gene panels appear to be an appropriate NGS methodology for di-
rected diagnosis. These panels must be designed to include both the
NPC1 andNPC2 geneswith complete exons and exon-intron boundaries.
As genomic deletions and deep intronic mutations are not exceptional
in this disease [25], in complex cases more detailed molecular charac-
terisation is required, and the need for sequencing of promoters and
deeper intronic regions should be assessed [4,10]. Sequencing of only
exons and exon–intron boundaries does not allow the identiﬁcation of
deep intronicmutations, mutations in regulatory regions, or large struc-
tural variants that may result in aberrant protein expression. Indeed,
mutations in NPC1 introns have been identiﬁed in patients with NP-C
andwere found to result in splicing defects [25,112,113]. Large structur-
al variants that encompass NPC1 and the ﬂanking genes have also been
described [114], as have whole gene deletions [25]. cDNA sequencing is
helpful to detect intronic problems and for identiﬁcation of splicemuta-
tions; several early NPC1mutational studies utilised cDNA sequencing
[28,115,116], and in some instances revealed the effect of complex ge-
nomic mutations. Multiplex ligation-dependent probe ampliﬁcation
(MLPA) and quantitative PCR can be used to detect genomic rearrange-
ments (exonic or whole gene deletions) [10,108,113,117], and assess-
ment of mRNA degradation (inhibition of nonsense-mediated mRNA
decay processes) has also been used to investigate mutations resulting
in aberrant splicing [10,25,118].
NGS methodologies can be used for gene panel sequencing, large-
scale genetic analysis, and whole exome and whole genome analyses,
and have recently been employed in NP-C screening and diagnosis. In
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tially suspected of amyotrophic lateral sclerosis because of positive fa-
milial history with affected cousins (despite differing symptoms), led
to the identiﬁcation, in both individuals, of a previously described [29]
homozygous NPC2mutation, which affects the cholesterol binding site
of NPC2 [120,121]. The diagnosis of NP-C was conﬁrmed after subse-
quent positive ﬁlipin staining results. In the original case [29], and an-
other adult-onset patient with the same genotype (P. Latour,
unpublished observations), NP-Cwas clinically suspected and diagnosis
was established using the ﬁlipin test prior to genotyping. This example,
besides supporting the power of exome sequencing, underscores the
importance of clinical awareness of NP-C. In another report, Herbst
and colleagues reported the use of multi gene panel sequencing for
inherited cholestatic disorders in childhood. They identiﬁed a novel
pathogenic mutation in NPC1 and conﬁrmed a previously reported
NPC1mutation in the same patient [122,123]. Sanger sequencing analy-
sis was subsequently used to conﬁrm compound heterozygous NPC1
mutations in the patient's mother and father [122]. Finally, gene panel
sequencing of 122 ataxia genes has also been used to identify NPC1
and NPC2mutations in individuals with unexplained early-onset ataxia
(EOA) [124]. These targeted analyses led to the identiﬁcation of two pa-
tients with NP-C, and revealed an enrichment of NPC1mutations in pa-
tients with EOA [124].
The expandeduse of NGS as a powerfulmethod for routinediagnosis
of Mendelian disorders will lead to the identiﬁcation of an increased
number of new variants, which may or may not be pathogenic and
which are a common interpretation problem [13,74,125]. Validation of
these mutations as pathogenic, rather than variants of no or unknown
clinical signiﬁcance, is highly challenging [125]. This is particularly
true in NP-C considering the size and polymorphic nature of the NPC1
gene [13,126].
A diagnosismay sometimes be difﬁcult to conﬁrmwith genetic anal-
ysis alone, and it is not uncommon that alternative laboratories or use of
different primers may reveal previously unidentiﬁed mutations. Com-
plex alleles with more than one NPC1 mutation have been described,
in some patients only one mutated allele has been identiﬁed, and in a
very small number of patients with clinical symptoms and other labora-
tory results suggestive of NP-C, no mutation could be found [4]. To ex-
plain the latter situation, the possibility that mutations in genes other
than NPC1 and NPC2 could cause NP-C has been raised. While this can-
not be formally excluded, other reasons are more likely to explain this
discrepancy, including diseases mimicking NP-C and inadequacies of
genetic testingmethodologies. Parental studies are another essential as-
pect of molecular characterisation to ensure allele segregation and to
conﬁrm an apparent homozygous status at the genomic level [10,117].
In case of ambiguous results in sequencing, the observation of normal
biomarkers and/or ﬁlipin test speaks against an NP-C diagnosis; on the
other hand, in combination with a slight elevation of biomarkers and/
or a variant ﬁlipin test, the data may also correspond to a heterozygous
state for NP-C.
Although Sanger sequencing still has a signiﬁcant place in the diag-
nostic process of NP-C, its use is likely to diminish over time, owing to
the wider availability of NGS and its acceptance as a reliable technique.
Gene panel sequencing has a greater capacity and ability to sequence
samples simultaneously, compared with targeted gene sequencing,
and thus can provide potential cost savings in certain cases [108].
Whole exome andwhole genome sequencing techniques, while beneﬁ-
cial for providing a wealth of data on genes of interest and capturing
mutations in genes other than NPC1 and NPC2, can be expensive and
may present signiﬁcant challenges in interpretation due to the volume
of data produced. Beneﬁts of these approaches include comprehensive
molecular analysis in uncertain cases and the increased capability to ex-
clude a diagnosis of NP-C. These techniques are not commonly used in
service laboratories or as diagnostic procedures and they should be lim-
ited to caseswith clear clinical and biochemical suspicion of the disease,
but no mutations identiﬁed using routine sequencing methods [108].Beyond diagnosis, identiﬁcation of NPC1 and/or NPC2 mutations
combined with descriptions of clinical phenotype, will improve our
knowledge of pathogenic mutations and our understanding of geno-
type–phenotype correlations. Mutational analysis is also the onlymeth-
od that supports reliable screening for heterozygous status in blood
relatives, and safe prenatal diagnosis in instances with at-risk parents
[4,10]. Together, this highlights the importance of conducting compre-
hensive genetic analyses in every patient.
4. Concluding remarks
This review is intended to increase awareness of the currently avail-
able approaches to laboratory diagnosis of NP-C, and to provide an up-
to-date, comprehensive and critical evaluation of the various methods.
Signiﬁcant advances, anticipated to have a positive impact on NP-C di-
agnosis, have been achieved in recent years with the development of
sensitive tests for NP-C using plasma samples, and the huge progress
in molecular genetic techniques.
Plasma biomarkers, currently C-triol and the lysosphingomyelin iso-
forms (and likely very soon, bile acid metabolites) appear today as
rapid, cost-effective and efﬁcient tests for ﬁrst screening. They are rela-
tively easy to implement in laboratories specialised in inherited meta-
bolic diseases, since many of those are already using LC-MS/MS
techniques. Cross-validation with standard samples is important; of
note, C-triol measurement is already included in some international
quality control programmes (e.g. ERNDIM). Nevertheless, these
methods are not without limitations: 1) elevated levels occur in dis-
eases other than NP-C; 2) normal levels do not necessarily exclude a di-
agnosis of NP-C; and 3) insufﬁcient data are available with respect to
these biomarkers in NP-C heterozygous individuals. A combination of
C-triol and lysosphingolipid measurements will likely decrease the pro-
portion of false negative diagnostic results; however, particularly for
lysosphingolipids, more experience within a clinical setting is still re-
quired to fully ascertain their potential. Newer tests recently validated
but currently still in development, such as bile acid derivatives, may
complement or possibly replace the current techniques. Nevertheless,
it should be kept in mind that these biochemical tests alone do not pro-
vide a deﬁnitive diagnosis.
Identifying two alleleswithNPC1 orNPC2 disease-causingmutations
will conﬁrm a diagnosis of NP-C. Genomic DNA sequencing has become
easier, faster and cheaper. The increased use of targeted NGS (e.g. ataxia
genes) or exome sequencing, has already led to the diagnosis of new
cases. But, as discussed in this review, sequencing of exons and exon–in-
tron boundaries will not allow the identiﬁcation of all mutations, and
complementary studies (e.g.MLPA, cDNA sequencing or more complex
techniques) may still be necessary. Further, parental studies are essen-
tial to avoid erroneous interpretation of data.
Amajor beneﬁt of genotyping is to allowprenatal diagnosis in at-risk
couples, and reliable genetic counselling in blood relatives. Achieving
genotyping for all index cases (including those where diagnosis was
established with ﬁlipin staining), is therefore of utmost importance.
Prenatal diagnosis of NP-C is currently achieved by mutation analysis
[4,10]. Notable exceptions can be pregnancies with echographic signs
of NP-C, but no index case. In such cases, a ﬁlipin test on cultured
amniocytes could be considered, as molecular genetic analysis may
incur pitfalls.
When properly conducted, the ﬁlipin test allows diagnostic conclu-
sions in the majority of cases, but it has many disadvantages and, like
mutational analysis, resultsmay be inconclusive. In practice, the two ap-
proaches are often complementary. A diagnosis may be supported by
the ﬁnding of known or certainly pathological mutations in a patient
with a ‘variant’ ﬁlipin proﬁle; likewise, mutations of uncertain pathoge-
nicity associated with clearly positive ﬁlipin staining will conﬁrm a
diagnosis.
In summary, all current NP-C diagnostic tests have their limitations,
but when used in combination, they lead to a correct diagnosis in the
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vidual testing. Genetic testing should include analysis of at least one of
the parents, which may be a limitation in adult cases. Following clinical
orientation, it seems logical today to ﬁrst enlist plasma biomarkers (if
possible a panel), usually followed by genetic testing in case of an
“NPC” proﬁle, with ﬁlipin test mandatory only in the some 15% of
cases inwhichmolecular results remain inconclusive. Mutation analysis
is essential in all cases, as ultimate conﬁrmation of the diagnosis, and as
a requisite for prenatal diagnosis and carrier detection. Diagnosis can
however remain a difﬁcult task in some patients. Expertise and refer-
ence laboratories thus remain essential, and further work is still needed
to develop a deﬁnitive and rapid NPC test. World-wide, the current
strategy used for laboratory diagnosis of NPC may however differ from
country to country, depending on local facilities, resources and
healthcare constraints. Particularly in the case of practical limitations,
but also because improved approaches are likely to be developed, it is
advisable to keep samples from suspected patients in biobanks for use
in future studies.
For many patients, the main problem today is still not the months
that may be needed to establish the diagnosis, but the years during
which NP-C was not suspected, and no disease-speciﬁc test carried
out. To introduce and establish therapy early in the disease course,
and to provide appropriate genetic counselling, a prompt diagnosis is
essential. This requires better recognition of the symptoms in clinical
practice and referral of samples for appropriate diagnostic testing. Ef-
forts to increase awareness of NP-C among clinicians are still needed,
but the recent development of rapid and relatively simple laboratory
tests should be of great help. Such assays could become part of wider
screening panels used in target populations, leading to more speciﬁc
tests in case of abnormal results.
Finally, systematic genotyping and the reappraisal and updating of
theNP-C gene variation database [109], as part of an ongoing EUproject,
will provide a useful prospective tool. This database should help to dis-
criminate between pathogenic and non-pathogenic gene variations and
— potentially in combination with existing or new biomarkers—, ex-
pand our currently limited knowledge of genotype–phenotype
correlations.
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